Key Takeaways
Alvotech (NASDAQ: ALVO) received a formal notice of inspectional observations from the U.S. Food and Drug Administration for its Reykjavik, Iceland, facility just as it reported a 20 percent drop in quarterly revenue caused by production slowdowns at the site.
The biotechnology company said the observations, detailed in a Form 483 issued May 8, can be addressed quickly and do not raise substantial issues with the site. Alvotech stated it remains on track to resubmit Biologics License Applications (BLAs) for several biosimilar candidates in the second quarter.
The regulatory notice adds pressure after a self-imposed manufacturing slowdown to improve quality systems contributed to a 20 percent year-over-year revenue decline to $106 million in the first quarter. The reduced throughput squeezed product margin to 11 percent and drove operating cash flow to negative $25 million. Despite the headwinds, Alvotech reaffirmed its full-year revenue guidance of $650 million to $700 million, projecting that the fourth quarter will be its strongest.
The Form 483 presents a new hurdle for Alvotech as it works to get pending biosimilar applications back on track for expected approvals in 2026. The company’s ability to resolve the FDA’s latest findings without delaying its Q2 resubmission timeline is critical to hitting its financial targets and achieving a goal of positive free cash flow by the end of the year.
While production has been constrained, the company’s commercial operations showed underlying strength. Its Humira biosimilar (AVT02) has become the fastest-growing biosimilar to the blockbuster drug in the United States, capturing about 10 percent of the biosimilar market segment, according to the company. To mitigate risks associated with its single manufacturing site, Alvotech recently signed a deal with Fujifilm to add U.S.-based manufacturing capacity, with product supply expected to begin in the second half of 2027.
The company must now prove it can resolve the new FDA observations while normalizing production at its Iceland facility. Investors will be watching for the successful BLA resubmissions in the current quarter, which Alvotech sees as a key step toward securing multiple U.S. approvals later this year.
This article is for informational purposes only and does not constitute investment advice.
